{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:08:46Z","timestamp":1777514926519,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021D00014, 75N93022F00001"],"award-info":[{"award-number":["75N93021D00014, 75N93022F00001"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The standard treatment for tuberculosis is the isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) regimen. Despite its efficacy, this regimen has limitations, including prolonged treatment duration and poor clinical outcomes in drug-resistant cases. This back translational study assessed the efficacy of alternative drug combinations, focusing on high-dose rifamycins (rifampicin and rifapentine) and substituting moxifloxacin for ethambutol in the HRZE regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a preclinical high-burden aerosol model of tuberculosis in BALB\/c mice, we tested seven treatment combinations, including high-dose rifampicin (HD-RIF), high-dose rifapentine (HD-RPT), and moxifloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      By day 12, the HD-RIF+HZM and HD-RPT+HZM regimens reduced lung bacterial burdens from 6.59 \u00b1 0.08 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU in untreated controls to 3.70 \u00b1 0.19 and 3.91 \u00b1 0.43 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU, respectively. By day 54, bacterial loads were undetectable (&amp;lt;1 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU) in all groups except for HRZE (1.48 \u00b1 0.32 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU). RS ratio analysis showed lower ratios for HD-RIF+HZM and HD-RPT+HZM compared to HRZE by day 26, indicating a superior ability of both regimens to interrupt rRNA synthesis. Histopathological analysis revealed similar granulomatous changes across all treatment groups. Mass spectrometry confirmed higher systemic exposure for HD-RIF and HD-RPT groups than RIF used in HRZE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The findings indicate that higher doses of rifamycins and the substitution of moxifloxacin offer improved bactericidal activity and could shorten TB treatment duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1667592","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:22:00Z","timestamp":1757924520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Jason E.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Woolhiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machenzie","family":"Wernsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Belisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Slayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/thoraxjnl-2020-216497","article-title":"High-dose rifamycins in the treatment of TB: a systematic review and meta-analysis","volume":"77","author":"Arbiv","year":"2022","journal-title":"Thorax"},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/cid\/ciaf004","article-title":"Safety of triple-dose rifampin in tuberculosis treatment: a systematic review and meta-analysis","volume":"81","author":"Arbiv","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1010823","DOI":"10.1371\/journal.pcbi.1010823","article-title":"Optimizing tuberculosis treatment efficacy: comparing the standard regimen with Moxifloxacin-containing regimens","volume":"19","author":"Budak","year":"2023","journal-title":"PLoS Comput. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month Rifapentine-Moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - united States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B7","volume-title":"NCT00864383","year":"2017"},{"key":"B8","volume-title":"NCT02410772","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0154778","DOI":"10.1371\/journal.pone.0154778","article-title":"A phase 2 randomized trial of a rifapentine plus moxifloxacin-based regimen for treatment of pulmonary tuberculosis","volume":"11","author":"Conde","year":"2016","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0231021","DOI":"10.1128\/aac.02310-21","article-title":"Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments","volume":"66","author":"Dide-Agossou","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/pharmaceutics15010009","article-title":"Safety of rifampicin at high dose for difficult-to-treat tuberculosis: protocol for RIAlta phase 2b\/c trial","volume":"15","author":"Espinosa-Pereiro","year":"2022","journal-title":"Pharmaceutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/cid\/ciaf003","article-title":"Safety, efficacy, and pharmacokinetics of daily optimized doses of rifampicin for the treatment of tuberculosis: a systematic review and bayesian network meta-analysis","volume":"81","author":"Espinosa-Pereiro","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: the opti-rif trial","volume":"76","author":"Garcia-Prats","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102857","DOI":"10.1016\/j.eclinm.2024.102857","article-title":"Efficacy and safety of higher dose rifampicin in adults with presumed drug-susceptible tuberculosis: an updated systematic review and meta-analysis","volume":"77","author":"Haigh","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"EVIDoa2300054","DOI":"10.1056\/EVIDoa2300054","article-title":"Four-month high-dose rifampicin regimens for pulmonary tuberculosis","volume":"2","author":"Jindani","year":"2023","journal-title":"NEJM Evid."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/AAC.00105-15","article-title":"Evaluation of moxifloxacin-containing regimens in pathologically distinct Murine tuberculosis models","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jcph.968","article-title":"A review of moxifloxacin for the treatment of drug-susceptible tuberculosis","volume":"57","author":"Naidoo","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0148322","DOI":"10.1128\/aac.01483-22","article-title":"Standardized RS ratio metrics to assess tuberculosis antimicrobial efficacy and potency","volume":"67","author":"Reichlen","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0058321","DOI":"10.1128\/AAC.00583-21","article-title":"Comparative analysis of pharmacodynamics in the C3HeB\/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832","volume":"65","author":"Robertson","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101875","DOI":"10.5409\/wjcp.v14.i2.101875","article-title":"Understanding antituberculosis drug-induced hepatotoxicity: risk factors and effective management strategies in the pediatric population","volume":"14","author":"Semwal","year":"2025","journal-title":"World J. Clin. Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","volume":"405","author":"Trajman","year":"2025","journal-title":"Tuberc. Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","article-title":"Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens","volume":"12","author":"Walter","year":"2021","journal-title":"Nat. Commun."},{"key":"B30","volume-title":"Global tuberculosis report 2024","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"822201","DOI":"10.3389\/fmed.2022.822201","article-title":"Intensified antituberculosis therapy regimen containing higher dose rifampin for tuberculous meningitis: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Med. (Lausanne)"}],"updated-by":[{"DOI":"10.3389\/fphar.2025.1733648","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1667592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:25:47Z","timestamp":1763468747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1667592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1667592"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1667592","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1667592"}}